HomeTagsEplontersen

Eplontersen

Ionis Announces Eplontersen Met Co-primary and Secondary Endpoints in Interim Analysis of the Phase 3 NEURO-TTRansform Study

Ionis Pharmaceuticals, Inc. announced positive topline results from a 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics